Hydrocortisone Sodium Phosphate

CHEMBL1200968 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
486.4 g/mol
LogP
Phase
4

A water-soluble sodium phosphate salt form of hydrocortisone used in injectable formulations for the acute treatment of severe allergic reactions, asthma attacks, adrenal crisis, and severe inflammation. Its high solubility allows rapid intravenous or intramuscular administration in emergency situations. This formulation provides fast onset of corticosteroid effect when oral treatment is not feasible.

Molecular Weight

486.4000 g/mol

TPSA

147.00 Ų

Therapeutic Areas

Mechanism of Action

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]

InChI

InChI=1S/C21H31O8P.2Na/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19;;/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28);;/q;2*+1/p-2/t14-,15-,16-,18+,19-,20-,21-;;/m0../s1

Molecular Formula

C21H29Na2O8P

HBD / HBA

2 / 8

Rotatable Bonds

3

Heavy Atoms

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A water-soluble sodium phosphate salt form of hydrocortisone used in injectable formulations for the acute treatment of severe allergic reactions, asthma attacks, adrenal crisis, and severe inflammation. Its high solubility allows rapid intravenous or intramuscular administration in emergency situations. This formulation provides fast onset of corticosteroid effect when oral treatment is not feasible.

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Yes, Hydrocortisone Sodium Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200968. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441406. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.